Results 71 to 80 of about 38,002 (265)

Application of Causal Inference to Establish Assay Effect in the Absence of a Bridging Study: A Case Study of MenACWY‐CRM Conjugate Vaccine Data

Pharmaceutical Statistics, Volume 25, Issue 2, March/April 2026.
ABSTRACT During a vaccine development program, if the assay used to measure immunological endpoints is changed, ideally, a bridging study is performed to establish the relationship between results obtained with the new and previous assay. However, this is not always feasible, and when bridging study data are absent, this can limit the ability to use ...
Meike Adani, Silvia Noirjean, Andrea Callegaro, Pavitra Keshavan, Marco Costantini   +4 more
wiley   +1 more source

Meningococcal Infection

Russian Pediatric Journal, 2023
.
openaire   +1 more source

Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020

American Journal of Hematology, Volume 101, Issue 2, Page 269-280, February 2026.
ABSTRACT There is limited information regarding the contemporary real‐world clinical and financial burden of Medicaid enrollees with sickle cell disease (SCD) in the United States. Using the IBM MarketScan Medicaid database (7/2016–12/2020), individuals with ≥ 3 SCD diagnoses were matched 1:1 on age, gender, and race to individuals without SCD ...
Giovanna Tedesco Barcelos, Telma Peixoto, Jose Alvir, Jay Lin, Christine L. Baker   +4 more
wiley   +1 more source

Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial

American Journal of Hematology, Volume 101, Issue 2, Page 242-254, February 2026.
ABSTRACT Iptacopan is a first‐in‐class, oral, selective inhibitor of complement factor B that has demonstrated positive efficacy across several complement‐driven diseases. Here we evaluate the efficacy and safety of iptacopan monotherapy in adult patients with primary immune thrombocytopenia (ITP) and primary cold agglutinin disease (CAD). We performed
Alexander Röth, Wilma Barcellini, Christine Ademokun, Junho Jang, Maria Luisa Lozano, David Valcarcel Ferreiras, Cristina Pascual‐Izquierdo, Shripad Chitnis, Sofiya Matviykiv, Alessandra Vitaliti, Chi Chen, Vasiliki Katsanou, Raghav Chawla, Hanny Al‐Samkari   +13 more
wiley   +1 more source

Fatal meningococcal meningitis in a HIV-infected patient caused by serogroup C Neisseria meningitidis belonging to the non-hypervirulent clonal complex ST-60 (cc60)

Brazilian Journal of Infectious Diseases
Meningococcal strains belonging to clonal complex cc60 are not associated with hypervirulent lineages and were never reported as causing disease in Latin American countries.
Claudia Ferreira de Andrade, Denise Cotrim da Cunha, Veronica Cavalcanti, Ivano de Filippis   +3 more
doaj   +1 more source

The Meningococcal Cysteine Transport System Plays a Crucial Role in Neisseria meningitidis Survival in Human Brain Microvascular Endothelial Cells

mBio, 2018
While Neisseria meningitidis typically exists in an asymptomatic nasopharyngeal carriage state, it may cause potentially lethal diseases in humans, such as septicemia or meningitis, by invading deeper sites in the body. Since the nutrient compositions of
Hideyuki Takahashi, Haruo Watanabe, Kwang Sik Kim, Shigeyuki Yokoyama, Tatsuo Yanagisawa   +4 more
doaj   +1 more source

Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections [PDF]

, 1995
Contains fulltext : 4804.pdf (publisher's version ) (Open ...
Bartelink, A.K.M., Dalen, R. van, Deuren, M. van, Meer, J.W.M. van der, Sauerwein, R.W., Ven-Jongekrijg, J. van der   +5 more
core   +3 more sources

Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry

Clinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa, Ema Rodrigues, Hiroyuki Murai   +2 more
wiley   +1 more source

Safety and efficacy of eculizumab in adult and pediatric patients with aHUS, with or without baseline dialysis [PDF]

, 2015
C
Hourmant, Maryvonne, Kincaid, John F, Legendre, Christophe M, Menne, Jan, van de Kar, Nicole CAJ, Vande Walle, Johan   +5 more
core   +1 more source

Systemic manifestations in the course of meningococcal disease [PDF]

, 2009
Background/Aim. Meningococcal disease most often manifests itself as meningitis or sepsis. During the course of these diseases, other clinical events sometimes develop such as pneumonia, pericarditis, arthritis, and they are referred to as extrameningeal
Dokić Ljubiša, Dulović Olga, Gvozdenović Eleonora, Milošević Branko, Nikolić Svetlana, Pavlović Milorad, Popović Nataša, Stevanović Goran   +7 more
core   +1 more source